Analysis of agranulocytosis in a child induced by vancomycin injection

doi:10.19803/j.1672-8629.20210813

Abstract

Abstract: Objective To provide reference for vancomycin injection induced adverse reaction—neutropenia/agranulocytosis. Methods A case report of four-year-old girl with agranulocytosis caused by vancomycin injection was analyzed by reviewing the related literature. Results A total of four related domestic and foreign reports were retrieved in this paper. It was found that all the five cases suffered from agranulocytosis or neutropenia to different extents after receiving vancomycin injection, and that the patients gradually recovered after vancomycin withdrawal or dosage reduction. Neutropenia in children might be related to the accumulation of vancomycin. Conclusion Routine plasma drug concentrations should be closely monitored when children receive vancomycin injection. The dosage of vancomycin should be reduced or stopped in case of agranulocytosis or neutropenia. If necessary, symptomatic treatments should be given.

Key words: vancomycin, agranulocytosis/neutropenia, children, adverse drug reaction

CLC Number:

R978
R994.11

CAO Xiaoyu, WANG Ying, WANG Jingwen, YANG Ruixia, GE Jie. Analysis of agranulocytosis in a child induced by vancomycin injection[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 106-109.

References

[1] FENG JH,QIAN Y.Advances in research on childhood neutropenia[J].Chin J Contemp Pediatr(中国当代儿科杂志), 2017, 19(4): 484-489.
[2] KESARWALA HH, RAHILL WJ, AMARAM N.Vancomycin induced neutropenia[J].Lancet, 1981, 317(8235): 1423.
[3] SHINOHARA YT, COLBERT J.Vancomycin-induced neutropenia during treatment of endocarditis in a pediatric patient[J]. Ann Pharmacother, 1994, 28(6): 723-726.
[4] JI HH,LUO J,SONG L,et al.Analysis of vancomycin-induced neutropenia adverse reactions/adverse events in children[J]. China Pharmacy(中国药房), 2016, 27(6): 760-762.
[5] CHENG GY, MA Z, JIANG Q, et al.Case analysis of vancomycin-induced febrile neutropenia in a child[J]. Chinese Journal of Drug Application and Monitoring(中国药物应用与监测), 2019, 16(4): 253-255.
[6] NARANJO CA, BUSTO U, SELLERS EM, et al.A method for estimating the probability of adverse drug reactions[J]. Clin Pharmacol Ther, 1981, 30(2): 239-245.
[7] Center for Drug Reevaluation. Provisions for Adverse Drug Reaction Reporting and Monitoring(《药品不良反应报告和监测管理办法》培训教材)[M]. 2015 edition.Beijing: China Medical Science and Press, 2012.
[8] LIU LY, LI Y, GU SY.Retrospective analysis of 38 granulocytopenia cases induced by vancomycin[J]. Chinese Journal of Pharmacovigilance(中国药物警戒) , 2012, 9(2): 117-118.
[9] BLACK E, LAU TT, ENSOM MH.Vancomycin-induced neutropenia: is it dose- or duration-related?[J]. Ann Pharmacother, 2011, 45(5): 629-638.
[10] SCHWARTZ MD.Vancomycin-induced neutropenia in a patient positive for an antineutrophil antibody[J].Pharmacotherapy, 2002, 22(6): 783-788.
[11] SMITH PF,TAYLOR CT.Vancomycin-induced neutropenia associated with fever: similarities between two immune-mediated drug reactions[J]. Pharmacotherapy, 1999, 19(2): 240-244.
[12] ROCHA JL, KONDO W, BAPTISTA MI, et al.Uncommon vancomycin-induced side effects[J]. Braz J Infect Dis, 2002, 6(4): 196-200.
[13] HE N, SU S, YE Z, et al.Evidence-based guideline for therapeutic drug monitoring of vancomycin: 2020 update by the division of therapeutic drug monitoring, chinese pharmacological society[J].Clin Infect Dis, 2020, 71(Suppl 4): S363-S371.

[1]	SUN Qiyue, ZHAO Ronghua, BAO Lei, GUO Shanshan, GENG Zihan, LI Shuran, XU Yingli, ZHANG Jingsheng, CUI Xiaolan, SUN Jing. Safe doses of Lingyang Ganmao oral liquid for children based on the multi-animal model [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 121-126.
[2]	JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166.
[3]	LI Yingfen, HAN Lei. Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198.
[4]	XU Weijia, PENG Qi, HUANG Haiyu, ZHANG Leijiao, XIAO Hua, WU Xue. 285 cases of adverse drug reaction related to new antineoplastic drugs [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 199-203.
[5]	GUO Qinghua, PENG Xiaoxiao, ZHU Ping, LIU Xilin, YANG Yinghua, CHEN Zhihai. One case of multiple organ dysfunction syndrome caused by amlodipine overdose [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 204-207.
[6]	FANG Meilin, ZHENG Huimin, WANG Cunze, WANG Ling, RUAN Junshan. One case of generalized myalgia caused by oxaliplatin [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 208-210.
[7]	CHEN Yuyan, ZHANG Mingxia, ZHANG Tao, ZHANG Jin. One case of interstitial pneumonia caused by serplulimab injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 213-215.
[8]	CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili. One case of severe liver injury caused by Tianma Shouwu tablets [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218.
[9]	GUO Longxin, GAO Yunjuan, WU Chengzhao, LONG Minjuan, ZHU Shengkai, SONG Haibo, ZHAO Xu, XIAO Xiaohe. Exploring new risk signals and susceptibility factors of traditional Chinese medicine-induced hepatotoxicity based on big data from adverse reaction monitoring [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 15-19.
[10]	JIANG Wenshuo, YANG Li. Adverse drug reaction among 694 patients in an epilepsy physician-pharmacist joint clinic [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 102-106.
[11]	CHEN Huayan, JIANG Dongbo, GUO Chunlian, YANG Jiaqi, LI Yuxin, CAI Weiming. Safety of nirmatrelvir/ritonavir in the treatment of novel coronavirus infections [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 107-110.
[12]	LIU Saiyue, LYU Xiaoqin, ZHOU Yun. Key points of investigation and report of suspected death of adverse drug reaction [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 971-974.
[13]	LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977.
[14]	PANG Yu, LIU Bo, LYU Shaoli, WANG Tao, XING Ying, QIN Xingyu, TIAN Yuejie, WU Wenyu. Exploring the significance of collecting patient reports based on international pharmacovigilance experience [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 978-981.
[15]	LIU Wendong, CUI Huanhuan, WANG Xiaohan, SU Xian, WANG Haixue. Status and thinking of Parmacovigilance regulatory system during clinical trials of the pediatric drug in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1002-1006.